Send to

Choose Destination
See comment in PubMed Commons below
Indian J Psychiatry. 2005 Apr;47(2):84-8. doi: 10.4103/0019-5545.55951.

Comparison of the efficacy and safety of moclobemide and imipramine in the treatment of depression in Indian patients.

Author information

  • 1Additional Professor of Psychiatry, Postgraduate Institute of Medical Education and Research.



Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA). Numerous studies have shown that moclobemide is well-tolerated and as effective as other antidepressants. So far, there is no evidence available regarding its efficacy and tolerability in India.


To compare the efficacy and safety of moclobemide with that of imipramine, a tricyclic antidepressant, in the treatment of major depressive disorder.


In this prospective study, patients (n=60) were randomly assigned to treatment with moclobemide or imipramine for 6 weeks. Efficacy of the drugs was assessed by observing the mean change in scores on the Hamilton Depression Rating Scale (HDRS) and the Montgomery-Asberg Depression Scale (MADRS).


Both the groups showed significant decrease in scores at the end of 6 weeks. Patients who received moclobemide had a better side-effect profile.


Moclobemide is an effective antidepressant and is better tolerated than imipramine.


Moclobemide; depression; monoamine oxidase-A inhibitor

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Write to the Help Desk